| Literature DB >> 26446631 |
Sung-Hwan Kim1, Yong-Seog Oh2, Gi-Byoung Nam3, Kee-Joon Choi3, Dae Hee Kim3, Jong-Min Song3, Duk-Hyun Kang3, Jae-Kwan Song3, You-Ho Kim3.
Abstract
PURPOSE: Although several studies have reported the morphological and electrical characteristics in patients with hypertrophic cardiomyopathy (HCM), comparison between asymmetric and apical HCM has not been investigated in a reasonably sized cohort.Entities:
Keywords: Hypertrophic cardiomyopathy; echocardiography; electrocardiography
Mesh:
Year: 2015 PMID: 26446631 PMCID: PMC4630037 DOI: 10.3349/ymj.2015.56.6.1515
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Demographic and Echocardiographic Characteristics
| Total (n=864) | Apical HCM (n=255) | Asymmetric HCM (n=553) | Mixed type HCM (n=56) | ||
|---|---|---|---|---|---|
| Age (yrs) | 55.4±14.2 | 59.9±11.8 | 52.9±14.9 | 59.3±11.6 | <0.001 |
| Men | 595 (68.9) | 182 (71.4) | 369 (66.7) | 44 (78.6) | 0.11 |
| LVOT obstruction | 163 (20.4) | 0 (0) | 159 (30.4) | 4 (7.4) | <0.001 |
| IVSs (mm) | 22.3±6.3 | 16.7±2.8 | 25.2±5.7 | 20.3±4.7 | <0.001 |
| IVSd (mm) | 18.1±6.4 | 11.7±2.4 | 21.2±5.4 | 15.9±4.6 | <0.001 |
| Left atrium (cm) | 44.2±6.8 | 44.2±6.9 | 44.2±6.8 | 43.3±6.6 | 0.45 |
| LVPWs (mm) | 17.4±3.6 | 17.3±2.8 | 17.4±3.9 | 17.2±3.8 | 0.82 |
| LVPWd (mm) | 11.3±2.7 | 11.5±2.1 | 11.3±2.9 | 10.9±2.8 | 0.26 |
| LVIDs (mm) | 26.6±5.9 | 28.6±4.9 | 25.6±6.1 | 27.5±5.0 | <0.001 |
| LVIDd (mm) | 46.0±6.2 | 49.3±5.3 | 44.4±6.0 | 47.9±5.5 | <0.001 |
| End systolic volume (mL) | 24.8±10.3 | 23.5±9.5 | 25.5±10.7 | 23.8±8.6 | 0.03 |
| End diastolic volume (mL) | 69.9±23.8 | 66.8±23.3 | 71.7±24.1 | 65.8±21.6 | 0.01 |
| IVSd/LVPWd | 1.7±0.6 | 1.0±0.1 | 2.0±0.5 | 1.5±0.3 | <0.001 |
| Ejection fraction (%) | 64.5±6.6 | 64.7±6.2 | 64.5±6.9 | 63.6±5.6 | 0.57 |
| E wave (m/sec) | 63.9±18.4 | 61.9±15.2 | 65.1±19.8 | 61.6±16.2 | 0.12 |
| A wave (m/sec) | 65.5±21.5 | 65.0±17.8 | 66.4±23.1 | 59.2±20.1 | 0.05 |
| Deceleration time (msec) | 222.3±68.8 | 206.1±52.5 | 231.5±74.5 | 207.4±61.0 | <0.001 |
| Medications | |||||
| Beta blocker | 406 (47.7) | 104 (40.8) | 281 (50.8) | 21 (47.7) | 0.03 |
| Verapamil | 137 (16.1) | 32 (12.5) | 101 (18.3) | 4 (9.1) | - |
| Amiodarone | 55 (6.5) | 10 (3.9) | 43 (7.8) | 2 (4.5) | - |
| Sotalol | 8 (0.9) | 2 (0.8) | 3 (0.5) | 3 (6.8) | - |
| Propafenone | 1 (0.1) | 1 (0.4) | 0 (0) | 0 (0) | - |
| Flecainide | 3 (0.4) | 1 (0.4) | 2 (0.4) | 0 (0) | - |
| No medication | 361 (42.4) | 125 (49.0) | 214 (38.7) | 22 (50.0) | 0.01 |
HCM, hypertrophic cardiomyopathy; LVOT, left ventricular outflow tract; IVSd, interventricular septum end diastole; IVSs, interventricular septum end systole; LVPWs, left ventricular posterior wall end systole; LVPWd, left ventricular posterior wall end diastole; LVIDs, left ventricular internal diameter end systole; LVIDd, left ventricular internal diameter end diastole.
Fig. 1Proportion of hypertrophic cardiomyopathy type relative to patient's age. In contrast to asymmetric hypertrophy, the proportion of patients with apical hypertrophy increased with age.
Electrocardiographic Findings
| Total (n=864) | Apical HCM (n=255) | Asymmetric HCM (n=553) | Mixed type HCM (n=56) | ||
|---|---|---|---|---|---|
| Heart rate (per mins) | 67.5±14.7 | 68.0±14.9 | 67.5±14.6 | 65.1±14.5 | 0.29 |
| PR interval (msec) | 166.7±31.2 | 160.0±31.6 | 170.4±30.1 | 160.6±34.7 | <0.001 |
| QRS duration (msec) | 102.5±19.3 | 96.8±13.6 | 105.4±21.3 | 99.3±12.8 | <0.001 |
| Corrected QT interval (msec) | 439.5±27.5 | 438.1±24.1 | 439.9±29.2 | 441.2±24.6 | 0.77 |
| Atrial fibrillation | 70 (8.1) | 28 (11.0) | 39 (7.1) | 3 (5.4) | 0.14 |
| J point elevation in anterior leads | 0.001 | ||||
| <0.1 mV | 585 (67.7) | 192 (75.3) | 348 (62.9) | 45 (80.4) | |
| 0.1-0.2 mV | 169 (19.6) | 37 (14.5) | 123 (22.2) | 9 (16.1) | |
| >0.2 mV | 110 (12.7) | 26 (10.2) | 82 (14.8) | 2 (3.6) | |
| J point elevation in inferior leads | 0.28 | ||||
| <0.1 mV | 782 (90.5) | 230 (90.2) | 498 (90.1) | 54 (96.4) | |
| 0.1-0.2 mV | 57 (6.6) | 20 (7.8) | 35 (6.3) | 2 (3.6) | |
| >0.2 mV | 25 (2.9) | 5 (2.0) | 20 (3.6) | 0 (0) | |
| J point elevation in lateral leads | 0.29 | ||||
| <0.1 mV | 845 (97.8) | 251 (98.4) | 538 (97.3) | 56 (100) | |
| 0.1-0.2 mV | 12 (1.4) | 1 (0.4) | 11 (2.0) | 0 (0) | |
| >0.2 mV | 7 (0.8) | 3 (1.2) | 4 (0.7) | 0 (0) | |
| Amplitude of negative T wave (mV) | 0.6±0.5 | 0.8±0.5 | 0.5±0.4 | 0.7±0.5 | <0.001 |
HCM, hypertrophic cardiomyopathy.
Fig. 2Electrocardiographic abnormalities according to the type of hypertrophy. *Advanced electrical abnormalities such as QT prolongation, QRS widening, PR prolongation, and pathologic Q wave were more prevalent in patients with asymmetric hypertrophy. LV, left ventricle; QTc, corrected QT duration ≥480 msec; QRS, QRS duration ≥120 msec; PR, PR interval ≥200 msec; Q wave, pathologic Q wave; anterior J, J point in anterior leads ≥0.1 mV; inferior J, J point in inferior leads ≥0.1 mV; lateral J, J point in lateral leads ≥0.1 mV; AF, atrial fibrillation.
Fig. 3The amplitude T wave inversion according to the type of hypertrophic cardiomyopathy. HCM, hypertrophic cardiomyopathy.
Fig. 4Correlation between apical wall thickness and the amplitude of T wave inversion in patients with apical hypertrophy. No significant correlation was observed.